CTLA4

[Frontiers in Immunology] Scientists examined the effect of selectively blocking the function of sCTLA-4 on in vitro immune responses from volunteer healthy or melanoma patient PBMC samples.

[Bone] In type 2 diabetes mellitus mice scientists inhibited systemic activation of T cells with a fusion protein between the extracellular domain of Cytotoxic T-Lymphocyte Antigen 4 and the Fc domain of human immunoglobulin G.

[Molecular Therapy-Oncolytics] Scientists overview and discuss this new perspective, focusing on the most relevant candidates for this role among the variety of potential NK immune checkpoints.

[Purple Biotech Ltd. (GlobeNewswire, Inc.)] Purple Biotech Ltd. announced the expansion of an existing research agreement, led by Dr. Menashe Bar-Eli at The University of Texas MD Anderson Cancer Center, and will evaluate the potential efficacy of the combination of NT219, a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3, and immuno-oncology drugs, such as anti-CTLA4 or anti-PD1/PDL1 antibodies.

[Scientific Reports] The authors developed, characterized and assessed whether chimeric heavy chain only antibodies against CTLA4 were viable therapeutic candidates for the treatment of canine cancers.

[Nature Reviews Clinical Oncology] Scientists discuss the translational potential and clinical development of agents targeting both co-stimulatory and co-inhibitory T cell receptors.